We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dissection Essential for Breast Cancer Patients with Positive Ultrasound-Guided Axillary Node Biopsy

By MedImaging International staff writers
Posted on 28 May 2012
In contradiction to a trend in treatment options, breast cancer patients with suspicious lymph nodes should have an ultrasound-guided axillary node biopsy, and if that biopsy is positive these patients should undergo an axillary dissection, a new study showed.

The study, conducted at the University of Pittsburgh Medical Center (UPMC; PA, USA), compared 199 patients with a positive ultrasound-guided axillary node biopsy to 434 patients with a positive sentinel lymph node biopsy. “About 50% of patients with a positive ultrasound-guided axillary node biopsy had substantial lymph node involvement; they were staged pN2 or pN3 at axillary dissection compared to 16% of patients with a positive sentinel node biopsy, said M. Lee Spangler, MD, one of the authors of the study. “Our results suggest that patients who have a positive ultrasound-guided axillary node biopsy should have an axillary dissection because they have more extensive disease. Patients with a negative ultrasound-guided axillary node biopsy can undergo a sentinel lymph node biopsy instead,” said Dr. Spangler.

The Z0011 trial found no survival benefit if patients underwent sentinel node biopsy instead of axillary dissection. Sentinel node biopsy is a less costly surgical procedure. “In light of the Z0011 trial, some institutions have routinely abandoned ultrasound-guided axillary node biopsy of suspicious axillary nodes in patients who are candidates for sentinel node biopsy alone,” said Dr. Spangler. “Our study indicates that patients with a positive ultrasound-guided axillary node biopsy represent a distinct population and the results of the Z0011 trial probably should not be extrapolated to this group.”

The study’s findings were presented May 7, 2012, at the American Roentgen Ray Society annual meeting held in Vancouver (BC, Canada).

Related Links:

University of Pittsburgh Medical Center



Digital Radiography System (Ceiling Free)
Digix CF Series
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Digital Radiography System
DR-300
Ultrasound Needle Guidance System
SonoSite L25

Channels

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.